Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GEORGE ANSSTAS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1790988053
CMS profile
927175
Location
SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$119,482.06

121 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GEORGE ANSSTAS

NPI 1790988053 · CMS profile ID 927175

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790988053?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GEORGE ANSSTAS, NPI 1790988053, CMS profile ID 927175. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790988053?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). GEORGE ANSSTAS, NPI 1790988053, CMS profile ID 927175. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790988053?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
GEORGE ANSSTAS, NPI 1790988053, CMS profile ID 927175, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1790988053?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

121 matching records · $119,482.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 121 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–121 of 121.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novocure Inc. $1,092.0003/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677573963 CMS
Novocure Inc. $101.6403/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677573959 CMS
E.R. Squibb & Sons, L.L.C. $4,125.0003/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651323241 CMS
Novocure Inc. $94.1203/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677573975 CMS
Novocure Inc. $79.4503/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677573977 CMS
Novocure Inc. $152.0003/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677573979 CMS
Novo Nordisk Inc $125.0003/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703505777 CMS
E.R. Squibb & Sons, L.L.C. $796.5002/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651323243 CMS
E.R. Squibb & Sons, L.L.C. $88.8102/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651323245 CMS
Novocure Inc. $271.2702/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677573981 CMS
GENZYME CORPORATION $25.0002/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693981811 CMS
Novocure Inc. $2.0002/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677573953 CMS
Novocure Inc. $21.6802/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677573957 CMS
E.R. Squibb & Sons, L.L.C. $4,125.0002/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651323237 CMS
E.R. Squibb & Sons, L.L.C. $742.3401/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651323227 CMS
E.R. Squibb & Sons, L.L.C. $56.4401/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651323233 CMS
Novocure Inc. $5.0001/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677573965 CMS
Novocure Inc. $432.4101/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677573973 CMS
GENZYME CORPORATION $25.0001/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693981307 CMS
E.R. Squibb & Sons, L.L.C. $42.4101/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651323231 CMS
E.R. Squibb & Sons, L.L.C. $28.0001/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651323239 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $119,482.06 121
PY2020 $7,322.44 10
PY2021 $4,034.20 9
PY2022 $16,235.79 30
PY2023 $11,364.05 19
PY2024 $11,580.63 11
PY2025 $19,326.51 23

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $697,533.50 85
PY2024 Recipient $1,174.71 3
PY2024 Principal investigator $597,399.65 57
PY2023 Recipient $806.21 10
PY2023 Principal investigator $655,293.21 71
PY2022 Recipient $817.92 8
PY2022 Principal investigator $988,845.99 77
PY2021 Recipient $1,270.00 2
PY2021 Principal investigator $498,672.90 40
PY2020 Principal investigator $524,263.95 35
PY2019 Principal investigator $261,314.14 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

85 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,000.00 12/31/2025 Non-covered Recipient Entity
Washington University
IOV-EAP-402 No dispute reported 06/30/2026 1252498403
Principal investigator 1 Merck Sharp & Dohme LLC $37,894.34 12/31/2025 Non-covered Recipient Entity
Washington University School of Medicine
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 1232925145
Principal investigator 1 Merck Sharp & Dohme LLC $11,443.75 12/31/2025 Non-covered Recipient Entity
Siteman Cancer Center
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 1232926871
Principal investigator 1 Merck Sharp & Dohme LLC $31,824.00 12/22/2025 Non-covered Recipient Entity
Washington University School of Medicine in St. Louis
A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1232935877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,889.90 12/19/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184278862
Principal investigator 1 Immunocore Limited $4,825.86 12/15/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144137
Principal investigator 1 Immunocore Limited $6,468.06 12/15/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144139
Principal investigator 1 Immunocore Limited $3,007.02 12/15/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144141
Principal investigator 1 Genentech, Inc. $24,707.40 12/12/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211684430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,980.00 12/04/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184269001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $375.30 11/26/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184265559
Principal investigator 1 Immunocore Limited $4,700.28 11/19/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144131
Principal investigator 1 Immunocore Limited $621.00 11/19/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144133
Principal investigator 1 Immunocore Limited $7,079.40 11/19/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,291.50 11/14/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184261205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,545.05 11/14/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184261207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $153.90 11/06/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184257733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,445.80 11/06/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184257735
Principal investigator 1 Genentech, Inc. $1,069.00 10/31/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211684418
Principal investigator 1 Genentech, Inc. $1,645.20 10/31/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211684420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,705.20 10/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184252530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,997.81 10/16/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184250551
Principal investigator 1 Immunocore Limited $8,000.00 10/15/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144143
Principal investigator 1 Immunocore Limited $8,400.00 10/15/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144145
Principal investigator 1 Immunocore Limited $4,600.00 10/15/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144147
Principal investigator 1 Immunocore Limited $1,015.00 10/15/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144149
Principal investigator 1 Immunocore Limited $6,900.00 10/15/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144151
Principal investigator 1 Immunocore Limited $1,015.00 10/15/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144153
Principal investigator 1 Immunocore Limited $2,900.00 10/15/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144155
Principal investigator 1 Immunocore Limited $2,300.00 10/15/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144157
Principal investigator 1 Immunocore Limited $690.00 10/15/2025 Non-covered Recipient Entity
Washington University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212144159
Principal investigator 1 Genentech, Inc. $9,928.00 10/10/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211684416
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,404.90 10/03/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184244593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,533.70 09/18/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184240414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,980.00 09/11/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184236071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,545.05 09/04/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184235139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,997.81 08/26/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184230637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,291.50 08/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184229921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,641.54 08/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184229923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,536.20 08/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184229925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,230.20 08/07/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184226529
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,054.70 08/01/2025 Non-covered Recipient Entity
Washington University
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence No dispute reported 06/30/2026 1235991865
Principal investigator 1 ModernaTX, Inc. $16,944.57 08/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252985036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,639.35 07/31/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184222784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,829.28 07/31/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184222786
Principal investigator 1 ModernaTX, Inc. $232.20 07/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252985030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,997.81 07/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217681
Principal investigator 1 Genentech, Inc. $3,175.31 07/16/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211684414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,134.81 07/03/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184212635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,114.00 06/24/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184210608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,216.60 06/19/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184209093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,937.44 06/12/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184206171
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $90,191.88 06/05/2025 Non-covered Recipient Entity
Washington University
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors No dispute reported 06/30/2026 1235991867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,404.90 06/05/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184204115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,061.00 05/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184197521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,964.09 05/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184197523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,003.50 05/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184197525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,667.82 05/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184194585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,281.40 05/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184194587
Principal investigator 1 Genentech, Inc. $3,583.80 05/09/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211684410
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,130.43 05/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184191911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,352.60 05/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184191913
Principal investigator 1 ModernaTX, Inc. $18,460.71 04/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252985034
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,997.81 04/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184185257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,520.00 04/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184185259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,650.00 04/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184185261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,888.00 04/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184185263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,971.16 04/17/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184184762
Principal investigator 1 Merck Sharp & Dohme LLC $8,325.12 04/16/2025 Non-covered Recipient Entity
Washington University School of Medicine
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 1232925189
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,380.00 04/04/2025 Non-covered Recipient Entity
Washington University School Of Medicine
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors No dispute reported 06/30/2026 1235991813
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $85,377.88 04/03/2025 Non-covered Recipient Entity
Washington University
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 1235991863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,911.50 04/03/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184181626
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,880.80 03/20/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184175010
Principal investigator 1 Genentech, Inc. $1,000.00 03/11/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients No dispute reported 06/30/2026 1211684456
Principal investigator 1 Genentech, Inc. $1,645.20 03/07/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Ph 2 Randomized POC Study of PCV in 1L Melanoma No dispute reported 06/30/2026 1211684408
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,900.00 03/06/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184157137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,650.00 03/06/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184157139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 03/06/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184157141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,705.00 03/06/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184157143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,300.00 03/06/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184157145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,600.00 03/06/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184157147
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $34,407.05 02/06/2025 Non-covered Recipient Entity
Washington University School Of Medicine
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 1235991815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,696.40 01/29/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184149830
Principal investigator 1 ModernaTX, Inc. $31,865.81 01/16/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252985032
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,404.90 01/03/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184144800